The recent partnerships on Claudin 18.2-targeting agents between Chinese biotechs and big pharma have brought China innovation to a new phase that Chinese firms can be proud of, an executive from Keymed Biosciences, one of the Chinese biotechs involved in such deals, tells Scrip in an interview.

The French firm unveiled data from its pancreatic cancer trial showing Onivyde plus chemotherapy improved median PFS by just over a month compared with current treatment of choice but failed to beat its overall survival benchmark.

MD Anderson and the US National Cancer Institute lead the way with a series of recent alliances, highlighted in this special edition of Tech Transfer Roundup focused on oncology.

Novel candidate acquired from Ganymed in 2016 moves closer to first approval filing anywhere for a CLDN18-targeting antibody, and as a potential competitor for Opdivo in HER2-negative gastric cancer, following positive top-line Phase III results in the first-line combo setting. Results from GLOW trial in combination with CAPOX also awaited.